Comparative Pharmacology
Head-to-head clinical analysis: KETOCONAZOLE versus NIZORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOCONAZOLE versus NIZORAL.
KETOCONAZOLE vs NIZORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, impairing ergosterol synthesis and disrupting fungal cell membrane integrity.
Inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
200-400 mg orally once daily for superficial fungal infections; 400 mg orally once daily for systemic mycoses. Duration varies by indication.
Ketoconazole 200 mg orally once daily with food. For severe infections, increase to 400 mg once daily. Duration depends on indication.
None Documented
None Documented
Biphasic elimination: initial half-life 2-4 hours, terminal half-life 6-10 hours in adults. In severe hepatic impairment, half-life may be prolonged up to 12-20 hours.
Clinical Note
moderateKetoconazole + Tranilast
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tranilast."
Clinical Note
moderateKetoconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tolfenamic acid."
Clinical Note
moderateKetoconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Nimesulide."
Clinical Note
moderateBiphasic elimination: initial half-life ~2 hours, terminal half-life 6–10 hours in adults with normal hepatic function; prolonged in hepatic impairment.
Primarily metabolized in the liver; about 70% of the dose is excreted in feces via bile as metabolites, approximately 20-30% in urine (mostly as inactive metabolites), and less than 5% unchanged.
Approximately 70% of the dose is excreted unchanged in feces via biliary elimination, and about 20–35% is excreted in urine, with less than 1% as unchanged drug in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal
Ketoconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Risedronic acid."